2D Matrix Codes: which countries are already connected to the European Hub?
There is not much time left until the safety features have to be implemented. These features are required to comply with the Falsified Medicines Directive, which will enter into force on 9 February, 2019. Meanwhile, a number of national data storage and retrieval systems have joined the EU Hub, as the European Medicines Verification Organisation (EMVO) reported.
The FDA has published a draft guidance which is to standardise the data traceability of products. Find out how long traceability data for products need to be stored according to the new FDA guideline "Standardization of Data and Documentation Practices for Product Tracing".
Falsified Medicines Directive - securPharm status report for 2018
There isn't much time left until the safety features required in the future will have to be implemented in order to comply with the Falsified Medicines Directive which will enter into force on 9 February, 2019. The German initiative securPharm has published a status report in this issue for the year 2018. Read more about the "securPharm Status report 2018".
ICMRA recommendations on track & trace implementation
In October 2017, the ICMRA adopted recommendations on the implementation of Track and Trace (T&T) Systems to emphasise the importance of the complexity of these systems. This is relevant for regulatory authorities as well as for the pharmaceutical industry. Find out more about the ICMRA T&T recommendations.
Protection from Falsification of Medicinal Products - only a few Months until Track & Trace Start!
In a securPharm press release, it is pointed out that the new protection system for pharmaceuticals will be launched on 9 February 2019. It is strongly recommended to join soon, since it may be a close call for individual manufacturers otherwise. Find out more about the securPharm press release.
Version 9 of the EU Q&As on Safety Features published
Safety features, which will be mandatory in the future to put the Falsified Medicines Directive into practice, must be implemented by 9 February, 2019. The European Commission has published version 9 of their questions and answers on safety features in February 2018. Find more information on the EU's revised Q&A document on safety features.
USA: when is a product suspicious, when is it illegitimate?
A new FDA guideline is supposed to help the industry in identifying suspicious or illegitimate products. All trade partners are asked to initiate specific actions if such products turn up. Find out more about the FDA instructions in suspicious and illegitimate products.
Track & Trace: New Questions and Answers published by the EU
The next version 8.0 of the catalogue containing questions and answers on practical implementation and technical aspects of serialisation requirements as per delegated act EU 2016/161 has become available on 22 November. Find more information about version 8.0 of the Q&A on EU FMD DR regarding serialisation.
USA: Track & Trace Realisation Postponed by a Year
In June, the FDA reported that the enforcement of requirements for the safety of supply chains will be postponed by a year. The new date is now November 27, 2018. Find out more about the change of the date in the FD&C Act.
Positive Balance for Implementation of the Falsified Medicines Directive
The soon-to-be required safety features for the realisation of the Falsified Medicines Directive must be implemented by February 09, 2019. The German initiative securPharm strikes a positive mid-term balance. Read more on the securPharm press release.
New questions and answers about safety features - Version 7 of the EU Q&As published
The soon-to-be mandatory safety features for the implementation of the Falsified Medicines Directive have to be implemented by February 9th, 2019. The European Commission has published Version 7 of the questions and answers about safety features in June 2017. Find out more about the revised Q&A document of the EU about safety features.
EMA's updated Implementation Plan for the Introduction of Safety Features
The soon-to-be required safety features for the execution of the Falsified Medicines Directive have to be implemented by February 9th, 2019. The EMA has published an updated plan for the implementation of safety features on the packaging of centrally authorized products for human use. Read more about the EMA's implementation plan for safety features.
The current edition of the Swissmedic Journal 05/2017 and the Technical Interpretation I-SMI.TI.17 specify the requirements with regard to the independence and the obligation of presence of the Swiss QP.
New CMDh Q&A Document on the Implementation of the EU Falsified Medicines Directive
In March the CMDh published a new Q&A document to provide further guidance on the implementation of the EU Falsified Medicines Directive. Please find more information about the "CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive".
Pro Generika - New Shareholder in the securPharm Manufacturer Database
On 15 March 2017, a common press release was published to announce the joining of Pro Generika e.V. as shareholder in the ACS PharmaProtect GmbH (ACS). ACS was founded in 2012 with the aim of developing and operating the manufacturer database in Germany. Read more about the joining of Pro Generika e.V. in the ACS PharmaProtect GmbH.